Table 2.
Characteristics | Types | Study |
---|---|---|
Participants | Healthy | [33–35, 42] |
Healthy physically active | [15, 16, 41] | |
Healthy with light-to-moderate anxiety levels | [20, 40] | |
Healthy overweight/obese with mild/moderate symptoms of fatigue | [39] | |
Supplementation product | Manufactured | [15, 20, 33, 35, 39–41] |
Registered product® | [16, 42] | |
No reported | [34] | |
% Withanolides of the supplementation product | No less than 5% | [15, 20, 35, 41] |
No less than 10% | [16, 42] | |
35% | [39, 40] | |
No reported | [33, 34] | |
Total dose (mg) | 240 | [40] |
300 | [20] | |
500 | [16] | |
600 | [15, 35, 39, 41] | |
750–1000-1250 | [34] | |
1000 | [33, 42] | |
Duration | 2 weeks | [42] |
30 days | [34] | |
8 weeks | [15, 35, 39, 41] | |
60 days | [40] | |
90 days/12 weeks | [16, 20] | |
6 months | [33] | |
Dose schedule | a.m | [16] |
After breakfast | [20] | |
After dinner | [39, 40] | |
a.m. and p.m | [15, 33, 34] | |
No reported | [35, 41, 42] |
a.m. ante meridiem, p.m. post meridiem, mg milligrams